Literature DB >> 28679551

Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials.

Mads F Hjorth1, Christian Ritz2, Ellen E Blaak3, Wim Hm Saris3, Dominique Langin4,5,6,7, Sanne Kellebjerg Poulsen2,8, Thomas Meinert Larsen2, Thorkild Ia Sørensen9,10,11, Yishai Zohar12, Arne Astrup2.   

Abstract

Background: Which diet is optimal for weight loss and maintenance remains controversial and implies that no diet fits all patients.Objective: We studied concentrations of fasting plasma glucose (FPG) and fasting insulin (FI) as prognostic markers for successful weight loss and maintenance through diets with different glycemic loads or different fiber and whole-grain content, assessed in 3 randomized trials of overweight participants.Design: After an 8-wk weight loss, participants in the DiOGenes (Diet, Obesity, and Genes) trial consumed ad libitum for 26 wk a diet with either a high or a low glycemic load. Participants in the Optimal well-being, development and health for Danish children through a healthy New Nordic Diet (OPUS) Supermarket intervention (SHOPUS) trial consumed ad libitum for 26 wk the New Nordic Diet, which is high in fiber and whole grains, or a control diet. Participants in the NUGENOB (Nutrient-Gene Interactions in Human Obesity) trial consumed a hypocaloric low-fat and high-carbohydrate or a high-fat and low-carbohydrate diet for 10 wk. On the basis of FPG before treatment, participants were categorized as normoglycemic (FPG <5.6 mmol/L), prediabetic (FPG 5.6-6.9 mmol/L), or diabetic (FPG ≥7.0 mmol/L). Modifications of the dietary effects of FPG and FI before treatment were examined with linear mixed models.
Results: In the DiOGenes trial, prediabetic individuals regained a mean of 5.83 kg (95% CI: 3.34, 8.32 kg; P < 0.001) more on the high- than on the low-glycemic load diet, whereas normoglycemic individuals regained a mean of 1.44 kg (95% CI: 0.48, 2.41 kg; P = 0.003) more [mean group difference: 4.39 kg (95% CI: 1.76, 7.02 kg); P = 0.001]. In SHOPUS, prediabetic individuals lost a mean of 6.04 kg (95% CI: 4.05, 8.02 kg; P < 0.001) more on the New Nordic Diet than on the control diet, whereas normoglycemic individuals lost a mean of 2.20 kg (95% CI: 1.21, 3.18 kg; P < 0.001) more [mean group difference: 3.84 kg (95% CI: 1.62, 6.06 kg); P = 0.001]. In NUGENOB, diabetic individuals lost a mean of 2.04 kg (95% CI: -0.20, 4.28 kg; P = 0.07) more on the high-fat and low-carbohydrate diet than on the low-fat and high-carbohydrate diet, whereas normoglycemic individuals lost a mean of 0.43 kg (95% CI: 0.03, 0.83 kg; P = 0.03) more on the low-fat and high-carbohydrate diet [mean group difference: 2.47 kg (95% CI: 0.20, 4.75 kg); P = 0.03]. The addition of FI strengthened these associations.
Conclusion: Elevated FPG before treatment indicates success with dietary weight loss and maintenance among overweight patients consuming diets with a low glycemic load or with large amounts of fiber and whole grains. These trials were registered at clinicaltrials.gov as NCT00390637 (DiOGenes) and NCT01195610 (SHOPUS), and at ISRNCT.com as ISRCTN25867281 (NUGENOB).
© 2017 American Society for Nutrition.

Entities:  

Keywords:  diabetes; fiber; glucose; glycemic index; glycemic load; insulin; personalized nutrition; precision medicine; prediabetes; weight

Mesh:

Substances:

Year:  2017        PMID: 28679551     DOI: 10.3945/ajcn.117.155200

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  35 in total

1.  Baseline Metabolic Variables Do Not Predict Weight Regain in Premenopausal Women.

Authors:  Catia Martins; Barbara A Gower; Gary R Hunter
Journal:  Obesity (Silver Spring)       Date:  2020-05       Impact factor: 5.002

Review 2.  Obesity: Pathophysiology and Management.

Authors:  Kishore M Gadde; Corby K Martin; Hans-Rudolf Berthoud; Steven B Heymsfield
Journal:  J Am Coll Cardiol       Date:  2018-01-02       Impact factor: 24.094

Review 3.  The Science of Obesity Management: An Endocrine Society Scientific Statement.

Authors:  George A Bray; William E Heisel; Ashkan Afshin; Michael D Jensen; William H Dietz; Michael Long; Robert F Kushner; Stephen R Daniels; Thomas A Wadden; Adam G Tsai; Frank B Hu; John M Jakicic; Donna H Ryan; Bruce M Wolfe; Thomas H Inge
Journal:  Endocr Rev       Date:  2018-04-01       Impact factor: 19.871

4.  Ageing: Improvement in age-related cognitive functions and life expectancy by ketogenic diets.

Authors:  Arne Astrup; Mads Fiil Hjorth
Journal:  Nat Rev Endocrinol       Date:  2017-11-09       Impact factor: 43.330

5.  Predictors of long term weight loss maintenance in patients at high risk of type 2 diabetes participating in a lifestyle intervention program in primary health care: The DE-PLAN study.

Authors:  Aleksandra Gilis-Januszewska; Noël C Barengo; Jaana Lindström; Ewa Wójtowicz; Tania Acosta; Jaakko Tuomilehto; Peter E H Schwarz; Beata Piwońska-Solska; Zbigniew Szybiński; Adam Windak; Alicja Hubalewska-Dydejczyk
Journal:  PLoS One       Date:  2018-03-23       Impact factor: 3.240

Review 6.  Low-carbohydrate diets and cardiometabolic health: the importance of carbohydrate quality over quantity.

Authors:  John L Sievenpiper
Journal:  Nutr Rev       Date:  2020-08-01       Impact factor: 7.110

Review 7.  Treatment of Obesity in Mitigating Metabolic Risk.

Authors:  Sean P Heffron; Johnathon S Parham; Jay Pendse; José O Alemán
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

Review 8.  Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver.

Authors:  Gijs H Goossens; Johan W E Jocken; Ellen E Blaak
Journal:  Nat Rev Endocrinol       Date:  2020-11-10       Impact factor: 43.330

Review 9.  Dietary Management of Obesity: Cornerstones of Healthy Eating Patterns.

Authors:  Alissa D Smethers; Barbara J Rolls
Journal:  Med Clin North Am       Date:  2018-01       Impact factor: 5.456

Review 10.  Effects of Different Weight Loss Approaches on CVD Risk.

Authors:  Peter M Clifton; Jennifer B Keogh
Journal:  Curr Atheroscler Rep       Date:  2018-04-25       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.